Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 2/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2414127 | 0.91 | GAA (0.37) | GAALMNAALDH1A1POLBALOX15 | |
| SCHEMBL2410372 | 0.90 | GAA (0.40) | GAALMNAALDH1A1POLBALOX15 | |
| SCHEMBL2414302 | 0.77 | KMT2A (0.43) | GAATP53KMT2A | |
| SCHEMBL2416313 | 0.75 | KMT2A (0.47) | GAATP53KMT2A | |
| SCHEMBL12275265 | 0.71 | AOC3 (0.36) | POLBNPSR1SMN1; SMN2 | |
| SCHEMBL12274761 | 0.71 | MAPT (0.38) | GAALMNAPOLBSMN1; SMN2TP53 | |
| SCHEMBL12275540 | 0.69 | SMN1; SMN2 (0.46) | GAALMNAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL31540857 | 0.67 | KMT2A (0.50) | POLBTP53FABP7FABP5KMT2A | |
| SCHEMBL23918256 | 0.66 | KMT2A (0.49) | TP53FABP7FABP5KMT2A | |
| SCHEMBL7809928 | 0.66 | KMT2A (0.52) | POLBTP53FABP7FABP5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | PPARA, PPARD, PPARG | GAA 684/4885LMNA 3376/4885ALDH1A1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.